The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
-
BUSINESS Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
-
REGULATORY Social Security Budget Ceiling Looks Set to Continue 3 More Years: Honebuto Draft
June 12, 2024
-
REGULATORY Honebuto Draft Equivocal on Off-Year Price Cuts, but Focuses on FY2025 Revision
June 12, 2024
-
REGULATORY Label Revisions Ordered for Brimonidine, Finerenone, and More
June 12, 2024
-
BUSINESS Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
-
BUSINESS Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
-
BUSINESS US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
-
ACADEMIA Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
-
BUSINESS Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
-
REGULATORY MHLW to Issue Nitrosamine Risk Communication Guidance by June-End; Draft Now Ready
June 11, 2024
-
COMMENTARY Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
BUSINESS Susana Murteira Tapped as Amgen Japan President
June 11, 2024
-
REGULATORY Govt’s New Capitalism Council Proposes Extending Scope of Mixed-Billing Scheme
June 11, 2024
-
BUSINESS Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
-
BUSINESS Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
-
BUSINESS Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
-
REGULATORY Japan Enacts Bill to Amend Regenerative Medicine Safety Act, Clinical Trial Act
June 11, 2024
-
BUSINESS Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
-
BUSINESS Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…